DAGLA
ENSG00000134780
Target class
Enzyme
Chromosome
11
- Chemical probe available
- Yes
- Target name
- DAGLA
- Gene name
- Diacylglycerol lipase alpha
- Gene symbol
- DAGLA
- Previous gene symbols
- C11orf11
- Protein name
- Diacylglycerol lipase-alpha (DAGL-alpha) (DGL-alpha) (EC 3.1.1.116) (Neural stem cell-derived dendrite regulator) (Sn1-specific diacylglycerol lipase alpha)
- KIAA0659
- NSDDR
- DAGLALPHA
- Gene biotype
- Protein coding
- Gene family
- Lipases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 51
- Highest tissue expression
- 26.87
- Tissue specificity (Gini)
- 0.428
- Tissue specificity (tau)
- 0.811
- KEGG gene identifiers
- hsa:747
- Reactome pathways
- R-HSA-426048
- Protein interaction confidence
- 0.8258
- Protein interaction partners
- 10
- End position
- 61747003
- Start position
- 61680391
- Chromosome
- 11
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Postsynaptic density membrane
- Multi-pass membrane protein . Early endosome membrane
- Multi-pass membrane protein . Cell projection, dendritic spine membrane
- Multi-pass membrane protein . Note=Cycles between the cell surface and an intracellular endosomal compartment. Internalized by early endosomes via a clathrin-independent pathway before transport back to the postsynaptic membrane surface in a PKC-dependent manner. .
Publication evidence
- PubMed 27595600
- Tissue specificity (tau)
- 0.811342
- Expression inequality (Gini)
- 0.427578
Expression in transcripts per million
- Brain - Cortex
- 26.87
- Brain - Cerebellum
- 23.38
- Brain - Frontal Cortex (BA9)
- 20.2
- Brain - Cerebellar Hemisphere
- 12.73
- Brain - Anterior cingulate cortex (BA24)
- 12.6
Expression in transcripts per million
- Brain - Cortex26.87
- Brain - Cerebellum23.38
- Brain - Frontal Cortex (BA9)20.2
- Brain - Cerebellar Hemisphere12.73
- Brain - Anterior cingulate cortex (BA24)12.6
- Brain - Hippocampus8.39
- Brain - Nucleus accumbens (basal ganglia)7.92
- Brain - Caudate (basal ganglia)7.45
- Pituitary7.2
- Minor Salivary Gland7.16
- Esophagus - Mucosa6.86
- Brain - Putamen (basal ganglia)6.75
- Colon - Transverse6.75
- Testis6.5
- Brain - Hypothalamus6.48
- Brain - Amygdala6.43
- Prostate6.06
- Breast - Mammary Tissue6.01
- Uterus5.91
- Nerve - Tibial5.83
- Cervix - Endocervix5.54
- Fallopian Tube5.42
- Lung5.1
- Colon - Sigmoid4.73
- Small Intestine - Terminal Ileum4.57
And 29 more, listed on the interactive page.
- GO:0019369
- GO:0046340
- GO:0098921
- GO:0005886
- GO:0031901
- GO:0032590
- GO:0098839
- GO:0005515
- GO:0047372
Related records
Trials (58)
- A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss
- A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
- A Study of Xenical (Orlistat) in Overweight and Obese Adolescents
- A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
- A Trial With EMP16 in Preparation for Late Phase Studies
- Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder
- Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
- An RCT of Metformin Vs Orlistat in Obese Anovulatory Women
- Anti-obesity Effects of Dandelion (Taraxacum Officinale L.)
- Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine
- Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding
- Comparison of MAG and Fish Oil Efficacy
- Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects
- Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity
- Effect of Orlistat in Body Composition
- Effect of Orlistat on Metabolic and Hormonal Features in Women With Polycystic Ovary Syndrome (PCOS): a Randomized Controlled Clinical Trial
- Effectiveness of Brief Counseling for Weight Management
- Efficacy and Safety of ATL-962 in Obese Diabetics
- Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease